Allergy Diagnostics and Therapeutics Market to Grow at 9.1% CAGR, Fueled by Advanced Diagnostic Tools
The Global Allergy Diagnostics and Therapeutics Market is anticipated to reach USD 79.6 billion by 2033, up from USD 33.3 billion in 2023, growing at a compound annual growth rate (CAGR) of 9.1% during the forecast period from 2024 to 2033. This growth is driven by the rising prevalence of allergic disorders, such as allergic rhinitis and asthma, which affect millions globally. Technological advancements, including the use of artificial intelligence and mHealth apps, enhance diagnostic accuracy and patient management, further propelling market expansion.
Challenges in the market include the high cost of allergy diagnostics and treatments, which may limit accessibility, particularly in developing regions. Additionally, the lack of awareness about allergic conditions can impede early diagnosis and treatment, affecting market growth.
Recent developments highlight significant advancements in allergy diagnostics and therapeutics. For example, the introduction of innovative diagnostic tools like Proteomtech’s ‘Protea Allergy-Q 128M’ and Genentech’s FDA-approved prefilled syringe for Xolair demonstrate the market’s move towards more effective and accessible solutions. The increasing use of monoclonal antibodies and novel therapies like anti-IgE antibodies are expected to revolutionize treatment outcomes, offering targeted relief for allergy sufferers.
Regionally, North America dominates the market due to high healthcare expenditure and supportive government initiatives. Meanwhile, the Asia Pacific region is expected to experience substantial growth driven by rising healthcare reforms, expanding infrastructure, and an increasing prevalence of allergies.
Key Takeaways
- In 2023, the Allergy Diagnostics and Therapeutics market generated USD 33.3 billion and is projected to reach USD 79.6 billion by 2033, growing at a CAGR of 9.1%.
- The therapeutics segment dominated in 2023, accounting for over 82.8% of the total market revenue in Allergy Diagnostics and Therapeutics.
- Inhaled allergies were the largest contributor in 2023, holding a market share exceeding 50.6% among all allergy types.
- The in vitro test segment represented 53.6% of the market share in Allergy Diagnostics and Therapeutics in 2023.
- North America led the market with a revenue share of 38.1% in 2023, maintaining a strong regional presence.
Get Sample PDF Report: https://market.us/report/allergy-diagnostics-and-therapeutics-market/request-sample/
Allergy Diagnostics and Therapeutics Market Key Segments
By Type
- Therapeutics
- Antihistamines
- Decongestants
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Nasal Anti-cholinergic
- Immuno-modulators
- Epinephrine
- Immunotherapy
- Diagnostics
- Instruments
- Consumables
- Services
By Allergen Type
- Inhaled
- Food
- Dairy Products
- Poultry Product
- Tree Nuts
- Peanuts
- Shellfish
- Wheat
- Soys
- Other Food Allergens
- Drug
- Other Allergens
By Test Type
- In vitro Test
- In vivo Test
- Skin Prick Test
- Intradermal Test
- Patch Test
Key Regions
- North America (The US, Canada, Mexico)
- Western Europe (Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, Rest of Western Europe)
- Eastern Europe (Russia, Poland, The Czech Republic, Greece, Rest of Eastern Europe)
- APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Rest of APAC)
- Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, Rest of Latin America)
- Middle East & Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, Rest of MEA)
Buy Directly: https://market.us/purchase-report/?report_id=117335
Key Players Analysis
Thermo Fisher Scientific is a global leader in allergy diagnostics and therapeutics, offering comprehensive testing solutions through its ImmunoCAP products. These tests measure specific IgE antibodies to identify allergic triggers, including over 550 whole allergens and 100 allergen components. The company’s Phadia Laboratory Systems provide scalable and reliable platforms for conducting these tests, ensuring high-quality, reproducible results. Additionally, ImmunoCAP tests can be performed irrespective of age, medication, or skin conditions, providing a versatile tool for accurate allergy diagnosis and management.
Siemens Healthcare GmbH, a prominent player in the medical diagnostics field, offers advanced solutions in allergy diagnostics through its innovative immunoassay platforms. Siemens’ diagnostic tests are designed to detect specific IgE antibodies, which are crucial for identifying allergens and managing allergic diseases. The company’s systems are known for their accuracy, reliability, and integration capabilities, which streamline laboratory workflows and enhance diagnostic efficiency. Siemens’ commitment to innovation in diagnostic technologies helps improve patient outcomes by enabling precise and timely allergy detection and treatment.
R-Biopharm AG specializes in the development of diagnostic solutions for food allergies and intolerances. The company’s portfolio includes test kits for detecting specific allergens in various food products, which are essential for managing food allergies. R-Biopharm’s diagnostic tools are highly regarded for their sensitivity and specificity, enabling accurate detection of even trace amounts of allergens. These products support healthcare providers in diagnosing and monitoring allergic conditions, ultimately improving patient care and safety in the context of food allergies.
DASIT Group SPA is known for its comprehensive range of diagnostic products, including solutions for allergy testing. The company’s offerings include immunoassay systems that detect specific IgE antibodies, aiding in the diagnosis and management of allergic diseases. DASIT’s diagnostic platforms are designed to deliver reliable and precise results, supporting clinicians in making informed decisions about allergy treatments. The company’s focus on innovation and quality ensures that its diagnostic tools meet the highest standards in the healthcare industry.
bioMérieux is a global leader in in-vitro diagnostics, providing advanced solutions for allergy and autoimmune disease testing. The company’s diagnostic systems include immunoassays that detect specific IgE antibodies, which are critical for identifying allergens and managing allergic conditions. bioMérieux’s platforms are known for their accuracy, efficiency, and ease of use, making them valuable tools for healthcare providers. The company’s commitment to improving public health through innovative diagnostic solutions is reflected in its comprehensive product offerings for allergy diagnostics.
Allergy Diagnostics and Therapeutics Market Key Players:
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- R-Biopharm AG
- DASIT Group SPA
- bioMérieux
- Stallergenes Greer
- HYCOR Biomedical
- Minaris Medical America Inc.
- Omega Diagnostics Group PLC
- Lincoln Diagnostics
- HOB Biotech Group Corp.
- Other Key Players
Allergy Diagnostics and Therapeutics Market Report Scope >> Market Value (2023): USD 33.3 Billion || Forecast Revenue (2033): USD 79.6 Billion || CAGR (2024-2033): 9.1% || Base Year Estimation: 2023 || Historic Period: 2019-2022 || Forecast Period: 2024-2033.
Inquire More about report: https://market.us/report/allergy-diagnostics-and-therapeutics-market/#inquiry
About Market.US
Market.US is renowned for its comprehensive market research and analysis, providing customized and syndicated reports to a global clientele. Specializing in a variety of sectors, they offer strategic insights and detailed market forecasts, assisting businesses in making informed decisions. With a focus on innovation and accuracy, Market.US supports clients in over 126 countries, and maintains a strong repeat customer rate, underscoring their commitment to quality and client satisfaction. Their team excels in delivering exceptional research services, ensuring that no detail is overlooked in any target market.
Contact Details
Market.us (Powered By Prudour Pvt. Ltd.)
Contact No: +1 718 618 4351.
Email: inquiry@market.us
Blog: https://medicalmarketreport.com/
View More Trending Reports
Healthcare BPO Market Estimated To Reach USD 908 Billion By 2032, With Round About 9.9% CAGR
Dental 3D Printing Market Economic Projections Soar To USD 19.6 Billion By 2032, With 23.03% CAGR
Peptide Therapeutics Market Predicted USD 90 Billion By 2033, An Approximate 8.9% CAGR Growth
Editor Details
-
Company:
- Wired Release
- Website:
